Product image of Icatibant Aguettant (Icatibant) supplied by GNH India

Icatibant Aguettant

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Aguettant (Icatibant)

Icatibant, the active ingredient in Icatibant Aguettant, is a bradykinin B2 receptor antagonist presented as a solution for subcutaneous use. It treats hereditary angioedema (C1‑inhibitor deficiency) by providing rapid relief of acute swelling attacks in affected patients.

GNH India supplies Icatibant Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratoire Aguettant

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is a targeted therapy for hereditary angioedema that works by blocking the bradykinin B2 receptor pathway.

  • Hereditary angioedema type I: reduces severity and duration of acute swelling attacks.
  • Hereditary angioedema type II: provides rapid symptom relief during attacks.
  • Acute hereditary angioedema attacks: delivers fast onset of action to control life‑threatening edema.

How It Works

  • Icatibant acts as a competitive antagonist at the bradykinin B2 receptor, preventing bradykinin from binding and triggering vasodilation and increased vascular permeability. By blocking this receptor, the drug curtails the cascade that leads to the rapid swelling characteristic of hereditary angioedema, thereby limiting attack progression.

Side Effects

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or erythema: localized skin reddening.
  • Swelling at injection site: transient edema.
  • Nausea: occasional gastrointestinal upset.
  • Headache: mild to moderate intensity.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Hypersensitivity reactions: rash, urticaria, or anaphylaxis.
  • Severe hypotension: marked drop in blood pressure.
  • Paradoxical angioedema: worsening swelling despite therapy.
  • Thrombocytopenia: reduced platelet count.
  • Severe injection‑site necrosis: rare tissue damage.
  • Pulmonary edema: rare fluid accumulation in lungs.

Precautions & Warnings

Before using Icatibant, consider the following safety measures.

  • Pregnancy: safety not established; use only if potential benefit justifies the risk.
  • Breastfeeding: unknown excretion; weigh benefits against possible infant exposure.
  • Renal impairment: no dosage adjustment required, but monitor renal function.
  • Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced edema.
  • Hypersensitivity: discontinue immediately if severe allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with other agents that influence bradykinin pathways or edema risk.

Major Interactions (Avoid)

  • ACE inhibitors: additive bradykinin effect may exacerbate angioedema.
  • Neprilysin inhibitors (e.g., sacubitril): increase bradykinin levels, heightening risk.
  • C1‑inhibitor concentrates: may reduce Icatibant efficacy when used concurrently.

Moderate Interactions (Monitor Closely)

  • Estrogen‑containing contraceptives: can worsen hereditary angioedema symptoms.
  • NSAIDs: may increase propensity for swelling.
  • Beta‑blockers: could mask early signs of anaphylaxis or hypotension.

Frequently Asked Questions

Icatibant Aguettant is indicated for the treatment of acute attacks of hereditary angioedema caused by C1‑inhibitor deficiency (type I or II). It works by rapidly reducing swelling and alleviating symptoms during an episode.

Icatibant is a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑mediated vasodilation and increased vascular permeability, which are the primary drivers of swelling in hereditary angioedema.

The prescribed dose of Icatibant is determined by the treating physician based on the patient’s clinical condition and regulatory guidelines. Dosing instructions are provided on the prescription label and should be followed exactly.

Safety data for Icatibant in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas alternative therapies such as C1‑inhibitor concentrates replace the deficient protein and kallikrein inhibitors block upstream pathways. Icatibant offers rapid subcutaneous administration and is particularly useful for patients who prefer a self‑injectable option.

Icatibant should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Icatibant is administered by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or by the patient after appropriate instruction, using the pre‑filled syringe supplied with the product.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, paradoxical worsening of angioedema, and rare cases of thrombocytopenia. Patients should be monitored closely after injection, and any signs of severe reaction require immediate medical attention.

Icatibant is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients receiving ACE inhibitors or neprilysin inhibitors, as the combined effect on bradykinin may increase the risk of angioedema.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT